Neuromark Device
Payments companies reported to CMS as associated with Neuromark Device. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Neuromark Device, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Neuromark Device
These are the largest totals companies reported as associated with Neuromark Device. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Ronald Kuppersmith | College Station, TX | Otolaryngology | $189,793.49 |
| Marc Dubin | Baltimore, MD | Otolaryngology | $131,134.67 |
| Greg Davis | Puyallup, WA | Otolaryngology | $78,099.04 |
| Douglas Reh | Lutherville Timonium, MD | Otolaryngology | $31,891.25 |
| Masayoshi Takashima | Houston, TX | Otolaryngology | $31,575.51 |
| Anthony Delsignore | New York, NY | Otolaryngology | $30,189.68 |
| Brent Senior | Chapel Hill, NC | Otolaryngology | $22,907.30 |
| Michael Sillers | Birmingham, AL | Otolaryngology | $18,812.57 |
| Jeffrey Bedrosian | Portland, ME | Otolaryngology | $18,389.43 |
| Kibwei Mckinney | Oklahoma City, OK | Otolaryngology | $16,925.96 |
Prescribed Neuromark Device?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.